US House Democrat proposes ban on pharma ‘pay-for-delay’ deals
By Nick Robertson ( October 23, 2026, 20:39 GMT | Insight) -- A bill introduced in the US House on Thursday would prohibit, with some exceptions, branded drug manufacturers from compensating generic and biosimilar drugmakers to delay market entry through patent settlements, a tactic known as “pay-for-delay.”A US House Democrat introduced a bill Thursday that would bar so-called “pay-for-delay” schemes in pharmaceutical patent infringement litigation settlements....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.